偏好矩阵指导稀疏的正统相关性分析用于挖掘脑部成像阿尔茨海默氏病中的遗传关联
Jiahang Sha1, Jingxuan Bao1, Kefei Liu2
1Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, 3700 Hamilton Walk, Philadelphia, PA, 19104, USA.
Methods (San Diego, Calif.)
|July 28, 2023
概括
这项研究引入了一种新的方法,即偏好矩阵引导的稀疏正规相关性分析 (PM-SCCA),以更好地将遗传变异与阿尔茨海默病特征联系起来. 这种新的方法有效地识别了关键的遗传和表型标记,推进了基于遗传学的治疗策略.
科学领域:
- 定量遗传学 是一个量子遗传学.
- 基因组学就是基因组学.
- 生物统计学 生物统计学
背景情况:
- 了解遗传变异和表型特征之间的联系在定量遗传学中至关重要.
- 阿尔茨海默病的遗传标记和定量特征之间的关联还没有得到很好的定义,这阻碍了针对性治疗的发展.
- 现有的方法,如稀疏的正规相关性分析 (SCCA),缺乏整合先前生物知识的能力.
研究的目的:
- 开发一个改进的SCCA模型,包括先前的生物信息.
- 提高基因型-表型相关性和阿尔茨海默病生物相关标记物的识别.
- 为分析复杂的遗传数据引入一种简单而有效的计算方法.
主要方法:
- 开发了偏好矩阵引导的稀疏正规相关性分析 (PM-SCCA).
- 通过偏好矩阵将先前的知识整合到SCCA框架中.
- 使用模拟研究和真实世界阿尔茨海默病数据集验证了模型.
主要成果:
- 在PM-SCCA模型成功捕获了基因型-表型相关性.
- 该方法有效地确定了相关的遗传和表型特征.
- 与标准SCCA相比,在识别有意义的关联方面表现得更好.
结论:
- PM-SCCA提供了一种强大而灵活的方法,用于将先前的知识整合到相关性分析中.
- 这种方法可以显著帮助发现基因型-表型关系,特别是在阿尔茨海默氏症等复杂疾病中.
- 这些发现为更精确的基因诊断和治疗策略铺平了道路.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Alzheimer's Disease: Overview
524
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
524
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
